Gastric adenocarcinoma
JA Ajani, J Lee, T Sano, YY Janjigian, D Fan… - Nature reviews Disease …, 2017 - nature.com
Gastric cancers, with gastric adenocarcinoma (GAC) as the most common histological type,
impose a considerable global health burden. Although the screening strategies for early …
impose a considerable global health burden. Although the screening strategies for early …
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm
…, A Kawazoe, F Lordick, YY Janjigian… - Nature reviews Clinical …, 2021 - nature.com
Advances in cancer biology and sequencing technology have enabled the selection of
targeted and more effective treatments for individual patients with various types of solid tumour. …
targeted and more effective treatments for individual patients with various types of solid tumour. …
First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
…, ZA Cao, J Lu, P Bhagia, CS Shih, YY Janjigian - Future …, 2021 - Future Medicine
Treatment options for patients with HER2-positive advanced gastric cancer are limited, and
the prognosis for these patients is poor. Pembrolizumab has demonstrated promising …
the prognosis for these patients is poor. Pembrolizumab has demonstrated promising …
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma …
Background First-line chemotherapy for advanced or metastatic human epidermal growth
factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma …
factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma …
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Tumor molecular profiling is a fundamental component of precision oncology, enabling the
identification of genomic alterations in genes and pathways that can be targeted …
identification of genomic alterations in genes and pathways that can be targeted …
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers,
but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor …
but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor …
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
YY Janjigian, A Kawazoe, P Yañez, N Li, S Lonardi… - Nature, 2021 - nature.com
Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) amplification or
overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal …
overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal …
OncoKB: a precision oncology knowledge base
Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer
care, an urgent need exists for a clinical support tool that distills the clinical implications …
care, an urgent need exists for a clinical support tool that distills the clinical implications …
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M …
…, X Song, E de Stanchina, K Ohashi, YY Janjigian… - Cancer discovery, 2012 - AACR
EGF receptor (EGFR)–mutant lung cancers eventually become resistant to treatment with
EGFR tyrosine kinase inhibitors (TKI). The combination of EGFR-TKI afatinib and anti-EGFR …
EGFR tyrosine kinase inhibitors (TKI). The combination of EGFR-TKI afatinib and anti-EGFR …
[PDF][PDF] Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
Metastatic progression is the main cause of death in cancer patients, whereas the underlying
genomic mechanisms driving metastasis remain largely unknown. Here, we assembled …
genomic mechanisms driving metastasis remain largely unknown. Here, we assembled …